Effect of the combination of mitiglinide and metformin on glycemic control in patients with type 2 diabetes mellitus.

ABSTRACT:

Unlabelled

Aims/Introduction:  Mitiglinide is the newest drug in the meglitinide family. It increases the early-phase insulin release through rapid association-dissociation kinetics in the pancreatic β cells. The efficacy and safety of adding meglitinide to metformin monotherapy in patients with type 2 diabetes are unknown.

Materials and methods

  We carried out a prospective, randomized, multicenter trial to assess the efficacy and safety of combined treatment with mitiglinide and metformin for patients with type 2 diabetes who showed inadequate glycemic control with metformin monotherapy. Subjects with glycated hemoglobin (HbA1c) >7.0% after an 8-week metformin run-in phase were randomized to a 16-week trial phase with metformin plus mitiglinide (Met + Mit) or metformin pl

SUBMITTER: Cho YM 

PROVIDER: S-EPMC4008006 | biostudies-literature | 2010 Aug

REPOSITORIES: biostudies-literature